Developing new treatments for diseases caused by abnormal fibrosis
Official title: Platform technology to identify and develop first-in-class anti-fibrotic therapeutics through inhibition of collagen CP4H
Funded at Adiutrix Therapeutics · NIH-11007034 · Data updated 2026-11-12
This study is looking at new ways to treat diseases caused by excessive scarring in organs, like idiopathic pulmonary fibrosis and scleroderma, by understanding how certain cells trigger this scarring, so we can create better treatments that work well and have fewer side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Adiutrix Therapeutics NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 17, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $350,000 |
| NIH project number | 1R42HL176297-01 |
| Project ID | NIH-11007034 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with idiopathic pulmonary fibrosis, scleroderma, chronic kidney disease, or Crohn's disease.
✕Less likely to help
Patients with fibrotic diseases not related to the pathways being targeted in this research may not benefit.
What this research studies
This research focuses on creating innovative therapies to treat various diseases caused by abnormal fibrosis, which affects multiple organs. It aims to explore the mechanisms behind fibrosis, particularly how collagen synthesis is triggered by different pathways, including a newly identified mast cell-mediated pathway. By targeting these pathways, the research seeks to develop first-in-class anti-fibrotic therapeutics that could provide better outcomes than current treatments, which have limited efficacy and significant side effects. Patients with conditions like idiopathic pulmonary fibrosis, scleroderma, chronic kidney disease, and Crohn's disease may benefit from these new therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients suffering from fibrotic diseases.
How similar studies have gone: While there have been studies targeting the TGF-β pathway, this research explores a novel approach by investigating an additional mast cell-mediated pathway, making it a potentially groundbreaking effort.
Where this research is happening
-
Adiutrix Therapeutics
New York, United States Active
Researchers
- Principal investigator: Lennox, Ronald — Adiutrix Therapeutics
- Study coordinator: Lennox, Ronald
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.